Wilson disease:: clinical and biological aspects

被引:0
作者
Chappuis, P [1 ]
Bost, M
Misrahi, M
Duclos-Vallée, JC
Woimant, F
机构
[1] Hop Lariboisiere, APHP, Serv Biochim & Biol Mol, F-75475 Paris, France
[2] Hop Debrousse, Neurogenet Lab, Lyon, France
[3] Hop Bicetre, APHP, Lab Hormonol & Biol Mol, Le Kremlin Bicetre, France
[4] Hop Paul Brousse, APHP, Ctr Hepatobiliaire, Villejuif, France
[5] Hop Paul Brousse, APHP, Neurol Serv, Villejuif, France
关键词
Wilson disease; diagnosis;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Wilson disease is an autosomal recessive disorder of copper excess. This illness results from mutations of the ATP7B gene (chromosome 13, MIM# 277900). The discovery of the gene allowed a better understanding of cytosolic copper trafficking and its relationship with ceruloplasmin synthesis. Symptomatic patients may present with hepatic, neurologic or psychiatric forms. Clinical and phenotypic evidences provide only presumptive arguments for this disease which can be routinely assessed by molecular analysis. This genetic disease which can be efficiently treated was formerly biologically suspected after a careful but sometimes invasive study of copper metabolism. Genetic advances can now give a definite answer using linkage analysis and research for disease-causing mutations. However, this diagnosis strategy is limited since currently over 320 mutations and 80 polymorphisms have been currently identified.
引用
收藏
页码:457 / 466
页数:10
相关论文
共 32 条
[1]  
Ala Aftab, 2004, Clin Liver Dis, V8, P787, DOI 10.1016/j.cld.2004.06.005
[2]   COMPARISON OF SERUM COPPER DETERMINATION BY COLORIMETRIC AND ATOMIC-ABSORPTION SPECTROMETRIC METHODS IN 7 DIFFERENT LABORATORIES [J].
ARNAUD, J ;
CHAPPUIS, P ;
ZAWISLAK, R ;
HOUOT, O ;
JAUDON, MC ;
BIENVENU, F ;
BUREAU, F .
CLINICAL BIOCHEMISTRY, 1993, 26 (01) :43-49
[3]  
ARNAUD J, 1995, TECHNIQUE ANAL OLLGO, P77
[4]   Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine [J].
Bécuwe, C ;
Dalle, S ;
Ronger-Savlé, S ;
Skowron, F ;
Balme, B ;
Kanitakis, J ;
Thomas, L .
DERMATOLOGY, 2005, 210 (01) :60-63
[5]   Diagnosis of Wilson's disease: an experience over three decades [J].
Brewer, GJ .
GUT, 2002, 50 (01) :136-136
[6]   Treatment of Wilson disease with ammonium tetrathiomolybdate - III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy [J].
Brewer, GJ ;
Hedera, P ;
Kluin, KJ ;
Carlson, M ;
Askari, F ;
Dick, RB ;
Sitterly, J ;
Fink, JK .
ARCHIVES OF NEUROLOGY, 2003, 60 (03) :379-385
[7]  
COX DW, WILSON DIS
[8]   Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease [J].
Farinati, F ;
Cardin, R ;
D'Inca, R ;
Naccarato, R ;
Sturniolo, GC .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2003, 141 (06) :372-377
[9]   Diagnosis and phenotypic classification of Wilson disease [J].
Ferenci, P ;
Caca, K ;
Loudianos, G ;
Mieli-Vergani, G ;
Tanner, S ;
Sternlieb, I ;
Schilsky, M ;
Cox, D ;
Berr, F .
LIVER INTERNATIONAL, 2003, 23 (03) :139-142
[10]   Common mutations of ATP7B in Wilson disease patients from Hungary [J].
Firneisz, G ;
Lakatos, PL ;
Szalay, F ;
Polli, C ;
Glant, TT ;
Ferenci, P .
AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 108 (01) :23-28